User Fee Rates for FY 2009 Announced

Article

ePT--the Electronic Newsletter of Pharmaceutical Technology

The US Food and Drug Administration released its user fee rates for fiscal year 2009 last Friday.

Rockville, MD (Aug. 7)-The US Food and Drug Administration released its user fee rates for fiscal year (FY) 2009 last Friday. The new fees take effect Oct. 1, 2008, and remain in effect through Sept. 30, 2009.

FDA derives its authority to issue user fees from the Federal Food, Drug, and Cosmetic Act, and the Prescription Drug User Fee Amendments of 2007 (PDUFA IV). Below is a list of the new fees:

  • Application fees requiring clinical data: $1,247,200

  • Application fees not requiring clinical data: $623,600

  • Establishment fees: $425,600

  • Product fees: $71,520.

FDA estimates that there will be 25 establishment fee waivers in FY 2008 and probably another 10 in FY 2009 tied to orphan drugs per the Food and Drug Administration Amendments Act of 2007. The agency estimates there will be approximately 70 waivers, including exemptions tied to orphan drugs, for product fees in FY 2009 as there were in FY 2008.

The total fee revenue amount for FY 2009 is $510,665,000, including $35 million for drug safety compared with FY 2008 drug-safety fees of $25 million.

The new fee information is detailed in the Aug. 1 Federal Register, Docket No. FDA-2008-N-04271.


Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes